Directed evolution of adeno-associated virus yields enhanced gene delivery vectors
The DOI matches its Crossref record; 51 of the 53 references it cites were found in a registry or an index.
Abstract
Adeno-associated viral vectors are highly safe and efficient gene delivery vehicles. However, numerous challenges in vector design remain, including neutralizing antibody responses, tissue transport and infection of resistant cell types. Changes must be made to the viral capsid to overcome these problems; however, very often insufficient information is available for rational design of improvements. We therefore applied a directed evolution approach involving the generation of large mutant capsid libraries and selection of adeno-associated virus (AAV) 2 variants with enhanced properties. High-throughput selection processes were designed to isolate mutants within the library with altered affinities for heparin or the ability to evade antibody neutralization and deliver genes more efficiently than wild-type capsid in the presence of anti-AAV serum. This approach, which can be extended to additional gene delivery challenges and serotypes, directs viral evolution to generate 'designer' gene delivery vectors with specified, enhanced properties.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, directed evolution has been applied to generate AAV variants capable of evading neutralizing antibodies in vitro and in vivo.68–72”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [68]
In the citing paper
“New AAV variants created through directed evolution withstood up to 35-fold higher in vitro concentrations of pooled human antibodies than AAV2.”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [68]
In the citing paper
“These antibody neutralization properties also led to enhanced transduction in vivo, where AAV variants were capable of significantly higher transduction in the liver, heart and muscle than AAV2 in mice passively immunized with human antibodies.”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [68]
In the citing paper
“Compared with natural variants, the engineered AAV-DJ variant, consisting of residues from AAV2, AAV8, and AAV9 variants, has been shown to transduce hepatocytes in the presence of human intravenous IgG [194, 195].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [194]
In the citing paper
“The best-performing variants selected from this screen were reported to evade antibodies and enhance the gene expression [88].”
From Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy (2022) · cites this paper as [88]
Citations
Cites
Rapid evolution of a protein in vitro by DNA shuffling
Stemmer, W. P. C. (1994) · Nature · doi:10.1038/370389a0 · Cited by 1,932
Yeast surface display for screening combinatorial polypeptide libraries
Boder, E. T., & Wittrup, K. D. (1997) · Nature Biotechnology · doi:10.1038/nbt0697-553 · Cited by 1,760
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Summerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406
Zolotukhin, S., Byrne, B. J., Mason, E., Zolotukhin, I., Potter, M., Chesnut, K., Summerford, C., Samulski, R. J., & Muzyczka, N. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300938 · Cited by 1,312
Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070
Kay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022
Xiao, X., Li, J., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8098-8108.1996 · Cited by 912
Sonic hedgehog regulates adult neural progenitor proliferation in vitro and in vivo
Lai, K., Kaspar, B. K., Gage, F. H., & Schaffer, D. V. (2003) · Nature Neuroscience · doi:10.1038/nn983 · Cited by 799
Self-citationRabinowitz, J. E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., & Samulski, R. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.2.791-801.2002 · Cited by 762
Cited by
Items 501–535 of 535
Viral vectors for CNS disorders
Gray, S. J., Samulski, R. J., & Kalburgi, S. N. (2015) · doi:10.4155/fseb2013.13.23
Evans, D. (2009) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.1158992.619263
(2006) · Nature Methods · doi:10.1038/nmeth0306-155
Repaka, V., Lomboy, D., & Castro, P. (2022) · Berkeley Pharma Tech Journal of Medicine · doi:10.52243/bptjm.v1i2.28
Silveria, M. (2022) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/94095
Kwiatek, M., Michalski, A., Abramowicz, K., Rutyna, P., Wasiak, M., Reichert, M., & Lisowski, L. (2023) · Lekarz Wojskowy · doi:10.53301/lw/156374
“The capsid genes from wt AAV serotypes 1 through 12 were cloned into plasmid based on the pGEM-T Easy System (Promega, cat. no A1360) and served as templates for PCR. Genes coding for capsids were amplified in standard PCR reaction, mixes at 1:1 molar ratio, and digested with 0.1 U DNaseI (NEB, cat. no.”
InfluentialGene Expression and Editing in Mammalian Retinal Ganglion Cells
Tran, N. M., Xu, X., Qi, L. S., & Hu, Y. (2024) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-981-99-4436-1_19 · Cited by 1
The Use of AAV Vector-based Gene Therapy in the Treatment of Ophthalmic Diseases. Literature Review
Batyrova, Z. A., Murtazalieva, A. S., Ramazanova, J. M., & Batchaev, A. S. ‐. (2025) · Ophthalmology in Russia · doi:10.18008/1816-5095-2025-2-244-250
Barethiya, S., Huang, J. W., Liu, X., Guan, H., & Chen, J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.09.687530
“In CNN, the strides were [1,1] and the padding was valid.”
An AAV-Based Therapy Approach for Neurological Phenotypes of X-Linked Adrenoleukodystrophy
Gornostal, E. A., Alsalloum, A., Degtyarev, E., Kuznetsova, E., Levashova, A., Mishina, D., Mingaleva, N., Mazloum, A., Bogdanov, V. P., Krupinova, J. A., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311645
“Directed Evolution is a library-based screening approach in which random or rational mutational insertion is introduced to a specific site in the viral protein (VP) amino acid sequence [164–168].”
Ji, J., Lefebvre, E., & Laporte, J. (2024) · Figshare · doi:10.6084/m9.figshare.26715793
Ji, J., Lefebvre, E., & Laporte, J. (2024) · Figshare · doi:10.6084/m9.figshare.26715790
Ji, J., Lefebvre, E., & Laporte, J. (2024) · Figshare · doi:10.6084/m9.figshare.26715781
Ji, J., Lefebvre, E., & Laporte, J. (2024) · Figshare · doi:10.6084/m9.figshare.26715787
Ji, J., Lefebvre, E., & Laporte, J. (2024) · Figshare · doi:10.6084/m9.figshare.26715784
An Expanded Toolbox for Versatile Chemical Editing of Adeno‐Associated Virus
Pham, Q. T., Glicksman, J., Han, B., Koo, D., Loynd, C., Roy, S. J. S., & Chatterjee, A. (2026) · Angewandte Chemie · doi:10.1002/ange.202516157
Zempel, H. (2026) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2025.100
Evolution dirigée de virus adéno-associés pour un transfert de gène efficace dans le système visuel
Planul, A. (2017) · theses.fr (ABES) · doi:10.70675/c9b178a1z8ba4z4451za409z4e80a603376f · Cited by 1
Thermostability of Adeno-Associated Virus (AAV) Vectors
Pacouret, S. (2018) · theses.fr (ABES) · doi:10.70675/33e13ef9z7aefz418dz8fdez21352cc194bc
Nan, X., Sun, J., Jiao, Y., Li, W., Chen, Y., Liu, Y., Xu, B., Yu, L., Guo, W., & Wu, Y. (2026) · Human Gene Therapy · doi:10.1177/10430342261432669 · Cited by 1
“In contrast to rational design, it does not require prior knowledge of capsid structure or receptor interactions, 48 thereby enabling the discovery of novel capsid properties that are otherwise dif fi cult to achieve.”
Preclinical gene therapy using recombinant AAV vectors in mouse models of two human diseases
Günes, Y. Ö. (2022) · theses.fr (ABES) · doi:10.70675/52c9a808z1652z42c4zae82zc812b95f1723 · Cited by 1
Gardin, A. (2023) · theses.fr (ABES) · doi:10.70675/ac839ccez52b2z45bez9294ze72731823d9b · Cited by 1
Capsid Engineering of Adeno-Associated Viruses for Targeted Gene Therapy in Kidney Diseases
Ghaffarzadeh-Esfahani, M., & Gheisari, Y. (2026) · Human Gene Therapy · doi:10.1177/10430342261452215 · Cited by 1
“63 This approach involves generating extensive libraries of capsid variants through techniques such as error-prone polymerase chain reaction (PCR), DNA shuf fl ing, peptide insertion, and saturation mutagenesis.”
Gene therapy development for retinal diseases
Reichel, F. F., Bellingrath, J.-S., Király, P., & FISCHER, M. D. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-443-22212-2.00016-1
Viability of engineered AAVs via protein language modelsPreprint
Desrosiers, M., Ocari, T., Trinquier, J., Zin, E. A., Meter, T. V., Delmas, M., Tekinsoy, M., Planul, A., Nemoto, T., Dalkara, D., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.11.731521
Hong, Z., Zhang, Y., Zhang, J., Liu, H., Liu, Q., Li, Y., Yang, L., Li, L., Liu, Z., Yuan, Z., et al. (2026) · Advanced Science · doi:10.1002/advs.202519665
Status and future of recombinant adeno‐associated virus vector manufacturing
Agbogbo, F., & Dismuke, D. J. (2026) · Biotechnology Progress · doi:10.1002/btpr.88525
“104 Koerber et al. 105 with improved transduction properties.”
Park, S., Ji, E., Na, J., & Joo, K. I. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.180560
Nanobody-Functionalized AAV achieves Promoter-independent Neuronal Targeting in the CNS åPreprint
Extross, A., de Velasco, E. M. F., He, Y., Wickman, K., & Schmidt, D. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.18.752817
“B and AAV-PHP.eB and the retrograde-access variant AAV2-retro 5, 16–19 .”
CNS targeted AAV gene therapies: Recent advances and clinical insights
Brown, B. P., Lewis, R. W., Jr., & Davidson, B. L. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103118
Development of AAV vectors for the therapy of autoimmune and inflammatory diseases
Li, C., Hirsch, M. L., & Samulski, R. J. (2010) · Springer eBooks · doi:10.1007/978-3-0346-0165-8_11
“fling), to escape AAV2 neutralizing antibodies [ 59 ].”
BackgroundDoyal, M. F. (2015) · D-Scholarship@Pitt (University of Pittsburgh)
TREATMENTS (NON-ANTIEPILEPTIC DRUGS) | Viral Vector Approaches for Antiepileptic Gene Therapy
McCown, T. J. (2009) · Elsevier eBooks · doi:10.1016/b978-012373961-2.00295-2
Metadata
- Authors
- Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V.
- Affiliations
- University of California, Berkeley (US)
- Abigail Wexner Research Institute (US)
- Corresponding author
- Schaffer, David V
- Venue
- Nature Biotechnology
- Published
- 2006-01-22
- Volume
- 24
- Issue
- 2
- Pages
- 198-204
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2102111681
- Cited by
- 538
- References
- 53
- Citations by year
- 2026: 20 · 2025: 20 · 2024: 29 · 2023: 31 · 2022: 31 · 2021: 25 · 2020: 31 · 2019: 33 · 2018: 19 · 2017: 26 · 2016: 23 · 2015: 33 · 2014: 32 · 2013: 31 · 2012: 23
- FWCI
- 15.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Science Foundation
- ALS Association
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- adeno-associated virus, AAV2, directed evolution, viral capsid, gene delivery vectors, heparin binding, antibody neutralization, high-throughput selection
- MeSH terms
- Adenoviridae, Genetic Vectors, Transfection, Genetic Therapy, Drug Delivery Systems, Gene Targeting, Directed Molecular Evolution, Genetic Enhancement
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.